References
- Batty N, Malouf GG, Issa JP. (2009). Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 280: 192-200.
- Blaheta RA, Cinatl J Jr. (2002). Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 22: 492-511.
- Bolden JE, Peart MJ, Johnstone RW. (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
- Bort R, Gomez-Lechon MJ, Castell JV, Jover R. (2004). Role of hepatocyte nuclear factor 3 gamma in the expression of human CYP2C genes. Arch Biochem Biophys 426: 63-72.
- Brodeur GM. (2003). Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
- Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, Ulrichova J, Anzenbacher P, Pavek P. (2007). Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos 35: 1032-1041.
- Cinatl J Jr., Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, Vogel JU, Doerr HW, Kornhuber B. (1996). Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 7: 766-773.
- Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL. (2008). Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 153: 657-668.
- Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. (2008). Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34: 206-222.
- Fisher JE, Nau H, Löscher W. (1991). Alterations in the renal excretion of valproate and its metabolites after chronic treatment. Epilepsia 32: 146-150.
- Furchert SE, Lanvers-Kaminsky C, Juürgens H, Jung M, Loidl A, Frühwald MC. (2007). Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 120: 787-1794.
- Hooven LA, Mahadevan B, Keshava C, Johns C, Pereira C, Desai D, Amin S, Weston A, Baird WM. (2005). Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells. Bioorg Med Chem Lett 15: 1283-1287.
- Hopkins-Donaldson S, Yan P, Bourloud KB, Muhlethaler A, Bodmer JL and Gross N. (2002). Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells. Oncogene 21: 6132-6137.
- Isojärvi JI, Turkka J, Pakarinen AJ, Kotila M, Rättyä J, Myllylä VV. (2001). Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy. Epilepsia 42: 930-934.
- Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK. (2006). Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci 94: 261-271.
- Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. (2005). Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 65: 3815-3822.
- Maris JM, Mathay KK. (1999). Molecular biology of neuroblastomas. J Clin Oncol 17: 2264-2279.
- Marks PA, Miller T, Richon VM. (2003). Histone deacetylases. Curr Opin Pharmacol 3: 344-351.
- Marks PA, Richon VM, Miller T, Kelly WK. (2004). Histone deacetylase inhibitors. Adv Cancer Res 91: 137-168.
- Michaelis M, Doerr HW, Cinatl J Jr. (2007). Valproic acid as anti-cancer drug. Curr Pharm Des 13: 3378-3393.
- Michaelis M, Suhan T, Cinatl J, Driever PH, Cinatl J Jr. (2004). Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. Int J Oncol 25: 1795-1799.
- Morgenstern BZ, Krivoshik AP, Rodriguez V and Anderson PM. (2004). Wilms' tumor and neuroblastoma. Acta Paediatr Suppl 93: 78-85.
- Myasoedova KN. (2008). New findings in studies of cytochromes P450. Biochemistry (Mosc) 73: 965-969.
- Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, Wood JR, Legro RS, Strauss JF 3rd, McAllister JM. (2004). Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 145: 799-808.
- Poljakova J, Eckschlager T, Hrabeta J, Hrebackova J, Smutny S, Frei E, Martinek V, Kizek R, Stiborova M. (2009). The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Biochem Pharmacol 77: 1466-1479.
- Rogiers V, Akrawi M, Vercruysse A, Phillips IR, Shephard EA. (1995). Effects of the anticonvulsant, valproate, on the expression of components of the cytochrome-P-450-mediated monooxygenase system and glutathione S-transferases. Eur J Biochem 231: 337-343.
- Rogiers V, Callaerts A, Vercruysse A, Akrawi M, Shephard E, Phillips I. (1992). Effects of valproate on xenobiotic biotransformation in rat liver. In vivo and in vitro experiments. Pharm Weekbl Sci 14: 127-131.
- Santini V, Gozzini A, Ferrari G. (2007). Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 8: 383-393.
- Servidei T, Morosetti R, Ferlini C, Cusano G, Scambia G, Mastrangelo R, Koeffler HP. (2004). The cellular response to PPARgamma ligands is related to the phenotype of neuroblastoma cell lines. Oncol Res 14: 345-354.
- Silva MF, Aires CC, Luis PB, Ruiter JP, Ijlst L, Duran M, Wanders RJ, Tavares de Almeida I. (2008). Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review. J Inherit Metab Dis 31: 205-216.
- Snykers S, Vanhaecke T, De Becker A, Papeleu P, Vinken M, Van Riet I, Rogiers V. (2007). Chromatin remodeling agent trichostatin A: a key-factor in the hepatic differentiation of human mesenchymal stem cells derived of adult bone marrow. BMC Dev Biol 7: 24-39.
- Van Lint C, Emiliani S, Verdin E. (1996). The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5: 245-253.
- Voigt A, Hartmann P and Zintl F. (2000). Differentiation, proliferation and adhesion of human neuroblastoma cells after treatment with retinoic acid. Cell Adhes Commun 7: 423-440.
- Wen X, Wang JS, Kivistö KT, Neuvonen PJ, Backman JT. (2001). In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 52: 547-553.